These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

289 related items for PubMed ID: 23151910

  • 1. (11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy.
    Ceci F, Castellucci P, Mamede M, Schiavina R, Rubello D, Fuccio C, Ambrosini V, Boschi S, Martorana G, Fanti S.
    Eur J Nucl Med Mol Imaging; 2013 Jan; 40(2):149-55. PubMed ID: 23151910
    [Abstract] [Full Text] [Related]

  • 2. Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?
    Castellucci P, Fuccio C, Rubello D, Schiavina R, Santi I, Nanni C, Allegri V, Montini GC, Ambrosini V, Boschi S, Martorana G, Marzola MC, Fanti S.
    Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):55-63. PubMed ID: 20848281
    [Abstract] [Full Text] [Related]

  • 3. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
    Castellucci P, Fuccio C, Nanni C, Santi I, Rizzello A, Lodi F, Franceschelli A, Martorana G, Manferrari F, Fanti S.
    J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
    [Abstract] [Full Text] [Related]

  • 4. The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level <0.5 ng/mL.
    Mamede M, Ceci F, Castellucci P, Schiavina R, Fuccio C, Nanni C, Brunocilla E, Fantini L, Costa S, Ferretti A, Colletti PM, Rubello D, Fanti S.
    Clin Nucl Med; 2013 Sep; 38(9):e342-5. PubMed ID: 23797218
    [Abstract] [Full Text] [Related]

  • 5. Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution.
    Marzola MC, Chondrogiannis S, Ferretti A, Grassetto G, Rampin L, Massaro A, Castellucci P, Picchio M, Al-Nahhas A, Colletti PM, Marcolongo A, Rubello D.
    Clin Nucl Med; 2013 Jan; 38(1):e26-32. PubMed ID: 23242060
    [Abstract] [Full Text] [Related]

  • 6. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
    Rodado-Marina S, Coronado-Poggio M, García-Vicente AM, García-Garzón JR, Alonso-Farto JC, de la Jara AC, Maldonado-Suárez A, Rodríguez-Fernández A.
    BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
    [Abstract] [Full Text] [Related]

  • 7. 11C-choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT.
    Ceci F, Castellucci P, Graziani T, Schiavina R, Brunocilla E, Mazzarotto R, Ntreta M, Lodi F, Martorana G, Fanti S.
    Eur J Nucl Med Mol Imaging; 2014 May; 41(5):878-86. PubMed ID: 24346416
    [Abstract] [Full Text] [Related]

  • 8. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?
    Castellucci P, Ceci F, Graziani T, Schiavina R, Brunocilla E, Mazzarotto R, Pettinato C, Celli M, Lodi F, Fanti S.
    J Nucl Med; 2014 Sep; 55(9):1424-9. PubMed ID: 24935990
    [Abstract] [Full Text] [Related]

  • 9. PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy.
    Giovacchini G, Picchio M, Scattoni V, Garcia Parra R, Briganti A, Gianolli L, Montorsi F, Messa C.
    Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1106-16. PubMed ID: 20306038
    [Abstract] [Full Text] [Related]

  • 10. Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5 ng/ml.
    Evangelista L, Cuppari L, Guttilla A, Gardi M, Agostini A, Ruggera L, Basso U, Saladini G.
    Nucl Med Commun; 2018 Mar; 39(3):260-267. PubMed ID: 29381584
    [Abstract] [Full Text] [Related]

  • 11. Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy.
    Giovacchini G, Picchio M, Parra RG, Briganti A, Gianolli L, Montorsi F, Messa C.
    Clin Nucl Med; 2012 Apr; 37(4):325-31. PubMed ID: 22391699
    [Abstract] [Full Text] [Related]

  • 12. PET/CT with (18)F-choline after radical prostatectomy in patients with PSA ≤2 ng/ml. Can PSA velocity and PSA doubling time help in patient selection?
    Chiaravalloti A, Di Biagio D, Tavolozza M, Calabria F, Schillaci O.
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1418-24. PubMed ID: 26791373
    [Abstract] [Full Text] [Related]

  • 13. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Jul; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 14. Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced 18F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy.
    Schillaci O, Calabria F, Tavolozza M, Caracciolo CR, Finazzi Agrò E, Miano R, Orlacchio A, Danieli R, Simonetti G.
    Eur J Nucl Med Mol Imaging; 2012 Apr; 39(4):589-96. PubMed ID: 22231016
    [Abstract] [Full Text] [Related]

  • 15. Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy.
    Giovacchini G, Picchio M, Coradeschi E, Bettinardi V, Gianolli L, Scattoni V, Cozzarini C, Di Muzio N, Rigatti P, Fazio F, Messa C.
    Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):301-9. PubMed ID: 19756592
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Targeted salvage lymphadenectomy in patients treated with radical prostatectomy with biochemical recurrence: complete biochemical response without adjuvant therapy in patients with low volume lymph node recurrence over a long-term follow-up.
    Winter A, Henke RP, Wawroschek F.
    BMC Urol; 2015 Feb 21; 15(1):10. PubMed ID: 25881245
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET/CT in restaging prostate cancer patients: a meta-analysis.
    Treglia G, Ceriani L, Sadeghi R, Giovacchini G, Giovanella L.
    Clin Chem Lab Med; 2014 May 21; 52(5):725-33. PubMed ID: 24310773
    [Abstract] [Full Text] [Related]

  • 20. Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer.
    Pelosi E, Arena V, Skanjeti A, Pirro V, Douroukas A, Pupi A, Mancini M.
    Radiol Med; 2008 Sep 21; 113(6):895-904. PubMed ID: 18414809
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.